SARS-CoV-2 人体挑战研究的免疫学考虑因素。
Immunological considerations for SARS-CoV-2 human challenge studies.
机构信息
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
出版信息
Nat Rev Immunol. 2020 Dec;20(12):715-716. doi: 10.1038/s41577-020-00472-0.
Abstract
The ethics and practicalities of controlled human infection with SARS-CoV-2 have been widely discussed. Potential risks are clear. The case in favour hinges upon whether these risks can be mitigated to an acceptable, very low, level and whether the studies will provide substantial benefits that could not readily be obtained by other means. Here, we discuss the immunological considerations relating to each side of this balance.
摘要
用 SARS-CoV-2 对人类进行可控感染的伦理和实际问题已被广泛讨论。潜在风险显而易见。支持该做法的依据在于这些风险能否被降低到可接受的、非常低的水平，以及这些研究是否能带来无法通过其他方法轻易获得的实质性益处。在此，我们讨论与这一平衡的每一方面相关的免疫学考虑因素。
相似文献
1
Immunological considerations for SARS-CoV-2 human challenge studies.SARS-CoV-2 人体挑战研究的免疫学考虑因素。
Nat Rev Immunol. 2020 Dec;20(12):715-716. doi: 10.1038/s41577-020-00472-0.
2
Vaccines for SARS coronavirus 2 and the new normal in vaccinology.严重急性呼吸综合征冠状病毒2疫苗与疫苗学的新常态
Rev Med Virol. 2021 Mar;31(2):e2229. doi: 10.1002/rmv.2229. Epub 2021 Mar 5.
3
Why Oxford's positive COVID vaccine results are puzzling scientists.为何牛津大学新冠疫苗的阳性结果令科学家们感到困惑。
Nature. 2020 Dec;588(7836):16-18. doi: 10.1038/d41586-020-03326-w.
4
Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？
Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.
5
Covid-19 vaccines: delivering protective immunity.新冠疫苗：提供保护性免疫
BMJ. 2020 Dec 17;371:m4838. doi: 10.1136/bmj.m4838.
6
[Vaccination immunology in SARS-CoV-2].[新型冠状病毒肺炎中的疫苗接种免疫学]
Ugeskr Laeger. 2021 Mar 15;183(11).
7
[Not Available].[无可用内容]。
Rev Med Suisse. 2020 Oct 7;16(709):1895.
8
Immunology of COVID-19.COVID-19 的免疫学。
Environ Microbiol. 2020 Dec;22(12):4895-4908. doi: 10.1111/1462-2920.15302. Epub 2020 Nov 25.
9
Immunology Lessons from the SARS-CoV-2 Pandemic.来自新冠疫情的免疫学经验教训。
Annu Rev Immunol. 2021 Apr 26;39:v-vii. doi: 10.1146/annurev-iy-39-030121-100001. Epub 2021 May 3.
10
Need to promote healthy lifestyle as primary prevention to the COVID-19 and to improve the immune response to vaccines.需要促进健康的生活方式作为 COVID-19 的初级预防措施，并提高对疫苗的免疫反应。
Acta Biomed. 2020 Nov 10;92(1):e2021026. doi: 10.23750/abm.v92i1.10788.
引用本文的文献
1
Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context.新冠病毒人体挑战研究中的风险、获益和社会价值：从历史背景看大流行决策
Monash Bioeth Rev. 2022 Dec;40(2):188-213. doi: 10.1007/s40592-022-00156-6. Epub 2022 Jun 15.
2
Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.公众对新型冠状病毒（SARS-CoV-2）人体挑战研究的态度：一项混合方法研究。
Wellcome Open Res. 2022 Feb 10;7:49. doi: 10.12688/wellcomeopenres.17516.1. eCollection 2022.
3
Pandemic vaccine testing: Combining conventional and challenge studies.大流行疫苗测试：常规研究与挑战研究相结合。
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):710-715. doi: 10.1002/pds.5429. Epub 2022 Mar 31.
4
Human Challenge Studies with Coronaviruses Old and New.人体挑战研究与新旧冠状病毒。
Curr Top Microbiol Immunol. 2024;445:69-108. doi: 10.1007/82_2021_247.
5
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?新冠病毒疫苗挑战试验是否存在独特的可推广性问题？
J Med Ethics. 2022 Sep;48(9):586-589. doi: 10.1136/medethics-2020-107109. Epub 2021 Jun 7.
6
Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.通过在挑战试验后进行注册前批准推出，加强和加速新型冠状病毒2疫苗的安全性监测。
Vaccine. 2021 Jun 11;39(26):3455-3458. doi: 10.1016/j.vaccine.2021.04.056. Epub 2021 Apr 30.
7
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.非药物干预措施在降低病毒接种量以减少感染 SARS-CoV-2 的易感性及潜在疾病严重程度方面的重要性。
Lancet Infect Dis. 2021 Sep;21(9):e296-e301. doi: 10.1016/S1473-3099(20)30982-8. Epub 2021 Feb 22.
8
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2.合并症与对 SARS-CoV-2 的适应性免疫反应改变有关。
JCI Insight. 2021 Mar 22;6(6):146242. doi: 10.1172/jci.insight.146242.
9
Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.通过低剂量挑战研究优先考虑第二代 SARS-CoV-2 疫苗。
Int J Infect Dis. 2021 Apr;105:307-311. doi: 10.1016/j.ijid.2021.02.038. Epub 2021 Feb 13.
10
Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.通过故意自然病毒暴露来测试 SARS-CoV-2 疫苗的功效。
Clin Microbiol Infect. 2021 Mar;27(3):372-377. doi: 10.1016/j.cmi.2020.12.032. Epub 2021 Jan 6.
Zotero 插件